Increased blood calcitonin has the strongest signal, but studies have shown that calcitonin levels are elevated in patients with medullary thyroid cancer (16, 17); therefore, the adverse event of increased blood calcitonin may be related to the disease condition and cannot be attributed to taking pralsetinib. Here, CALCA is linked to medullary thyroid gland carcinoma.